Misplaced Pages

Revision as of 05:44, 15 March 2013

This article may have too many section headers. Please help consolidate the article. (June 2012) (Learn how and when to remove this message)

This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (January 2011) (Learn how and when to remove this message)

Biguanide

Identifiers
CAS Number	56-03-1
3D model (JSmol)	Interactive image Interactive image
Beilstein Reference	507183
ChEBI	CHEBI:3095
ChemSpider	5726
ECHA InfoCard	100.000.229
EC Number	200-251-8
Gmelin Reference	240093
KEGG	C07672
PubChem CID	5939
CompTox Dashboard (EPA)	DTXSID7074664
InChI InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)Key: XNCOSPRUTUOJCJ-UHFFFAOYSA-N
SMILES :c(:)::c(:): NC(=N)NC(N)=N
Properties
Chemical formula	C2H7N5
Molar mass	101.113 g·mol
Related compounds
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is  ?) Infobox references

Biguanide can refer to a molecule, or to a class of drugs based upon this molecule. Biguanides can function as oral antihyperglycemic drugs used for diabetes mellitus or prediabetes treatment. They are also used as antimalarial drugs.

The disinfectant polyaminopropyl biguanide (PAPB) features biguanide functional groups.

Examples

Examples of biguanides:

• Metformin - widely used in treatment of diabetes mellitus type 2
• Phenformin - withdrawn from the market in most countries due to toxic effects
• Buformin - withdrawn from the market due to toxic effects
• Proguanil - an antimalarial drug.

History

Galega officinalis (French lilac) was used for diabetes treatment in traditional medicine for centuries. In the 1920s, guanidine compounds were discovered in Galega extracts. Animal studies showed that these compounds lowered blood glucose levels. Some less toxic derivatives, synthalin A and synthalin B, were used for diabetes treatment, but after the discovery of insulin they were forgotten for the next several decades. Biguanides were reintroduced into Type 2 diabetes treatment in the late 1950s. Initially phenformin was widely used, but its potential for sometimes fatal lactic acidosis resulted in its withdrawal from pharmacotherapy in most pharmacopeias (in the U.S. in 1977). Metformin has a much better safety profile, and it is the principal biguanide drug used in pharmacotherapy worldwide.

Pharmacotherapy

Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. Therefore, not only are they effective in Type 2 diabetics but they can also be effective in Type 1 patients in concert with insulin therapy.

Mechanism of action

The mechanism of action of biguanides is not fully understood. Mainly used in Type II Diabetes, Metformin is considered to increase insulin sensitivity in vivo, resulting in reduced plasma glucose concentrations, increased glucose uptake, and decreased gluconeogenesis.

However, in hyperinsulinemia, biguanides can lower fasting levels of insulin in plasma. Their therapeutic uses derive from their tendency to reduce gluconeogenesis in the liver, and, as a result, reduce the level of glucose in the blood. Biguanides also tend to make the cells of the body more willing to absorb glucose already present in the blood stream, and there again reducing the level of glucose in the plasma.

Side effects and toxicity

The most common side effect is diarrhea and dyspepsia, occurring in up to 30% of patients. The most important and serious side effect is lactic acidosis, therefore metformin is contraindicated in renal insufficiency. Renal functions should be assessed before starting metformin. Phenformin and buformin are more prone to cause acidosis than metformin; therefore they have been practically replaced by it. However, when metformin is combined with other drugs (combination therapy), hypoglycemia and other side effects are possible.

References

• Rang et al., Pharmacology, 5th Edition, 2003, p 388

• Biguanides